Prognostic assessment of lung adenocarcinoma patients with early-staging diseases: a nomogram based on coagulation-related factors
LL Wu, WK Lin, JY Qian, SS Ma, MJ Li… - European Journal of …, 2023 - academic.oup.com
OBJECTIVES Early-stage lung adenocarcinoma (ADC) has a great heterogeneity in
prognosis that is difficult to evaluate effectively. Thus, we developed and validated an …
prognosis that is difficult to evaluate effectively. Thus, we developed and validated an …
Change in cytokine profiles released by mast cells mediated by lung cancer-derived exosome activation may contribute to cancer-associated coagulation disorders
S Ben, X Huang, Y Shi, Z Xu, H Xiao - Cell Communication and Signaling, 2023 - Springer
Background Coagulation disorders are a significant cause of lung cancer mortality. Although
mast cells are known to play a role in coagulation abnormalities, their specific role in this …
mast cells are known to play a role in coagulation abnormalities, their specific role in this …
Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities
Simple Summary Non-small cell lung cancer (NSCLC) is a common diagnosis from which
many patients die. Blood tests reflecting systemic inflammation are routinely collected in the …
many patients die. Blood tests reflecting systemic inflammation are routinely collected in the …
The role of tissue factor in signaling pathways of pathological conditions and angiogenesis
Tissue factor (TF) is an integral transmembrane protein associated with the extrinsic
coagulation pathway. TF gene expression is regulated in response to inflammatory …
coagulation pathway. TF gene expression is regulated in response to inflammatory …
Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer
Q Zhang, K Peng, L Wang, RY Zhang… - Clinical and Applied …, 2023 - journals.sagepub.com
Podoplanin (PDPN) is known to play a role in thrombosis, metastasis of tumor cells, the
epithelial–mesenchymal transition (EMT), and immune response. The present study aim to …
epithelial–mesenchymal transition (EMT), and immune response. The present study aim to …
Application of a nomogram from coagulation-related biomarkers and C1q and total bile acids in distinguishing advanced and early-stage lung cancer
T Long, X Zhu, D Tang, H Li… - The International Journal …, 2024 - journals.sagepub.com
Background This study aimed to establish a nomogram to distinguish advanced-and early-
stage lung cancer based on coagulation-related biomarkers and liver-related biomarkers …
stage lung cancer based on coagulation-related biomarkers and liver-related biomarkers …
A diagnostic biomarker of acid glycoprotein 1 for distinguishing malignant from benign pulmonary lesions
Y Chen, Y Zhang, A Huang, Y Gong… - The International …, 2023 - journals.sagepub.com
Background The acid glycoprotein 1 (AGP1) is downregulated in lung cancer. However, the
performance of AGP1 in distinguishing benign from malignant lung lesions is still unknown …
performance of AGP1 in distinguishing benign from malignant lung lesions is still unknown …
Classification and immunotherapy assessment of lung adenocarcinoma based on coagulation-related genes
Y Zhou, W Fan, J Zhou, S Zhong, J Yang… - Personalized …, 2024 - Taylor & Francis
Introduction: This study on lung adenocarcinoma (LUAD), a common lung cancer subtype
with high mortality. Aims: This study focuses on how tumor cell interactions affect …
with high mortality. Aims: This study focuses on how tumor cell interactions affect …
出凝血检测在肿瘤患者中的应用价值探讨
王砚春, 卢仁泉 - 诊断学理论与实践, 2023 - qk.sjtu.edu.cn
出凝血功能异常是恶性肿瘤发生, 发展的重要特征. 肿瘤细胞释放促血管生成因子引起血管内皮
损伤, 并诱导血小板活化和增多, 均增加了血栓形成的风险. 肿瘤患者常表现为活化部分凝血活酶 …
损伤, 并诱导血小板活化和增多, 均增加了血栓形成的风险. 肿瘤患者常表现为活化部分凝血活酶 …
Albumin-to-D-dimer ratios: A novel prognostic factor for evaluating first-line chemotherapy efficacy in advanced lung adenocarcinoma patients.
L Zhang, LI Xing, W Zhuo, Z Zhang, L Zhang… - …, 2024 - search.ebscohost.com
The prognosis of advanced lung adenocarcinoma (LUAD) remains unfavorable, with
chemotherapy constituting a primary treatment modality. Discerning the efficacy of …
chemotherapy constituting a primary treatment modality. Discerning the efficacy of …